We have reviewed the antibiotic susceptibility profiles for 138 clinical isolates of B. pseudomallei obtained from the first positive clinical specimen from 138 melioidosis patients over 13 years. All isolates of B. pseudomallei (100%) tested against imipenem, amoxicillin/clavulanic acid, piperacillin/ tazobactam and meropenem were sensitive. Whereas little resistance was reported against ceftazidime (n=1, 0.7%), chloramphenicol (n=2, 2.1%), tigecycline (n=2, 0.4%) and cefipime (n=2, 2.3%). Up to half isolates tested for trimethoprim/sulphamethazole showed resistance (n=52, 38.3%). Results concurred with previous reports done in different geographical locations and showed the stability of the current treatment guidelines for melioidosis followed in our clinical sittings.
Prof. Dr. Bilal BİLGİN